pembrolizumab,lenvatinib
eisai,merck
['melanoma', 'neopele', 'pembro', 'lenva']
neopele #esmo22 another doublet showing high activity in #neoadjuvant therapy in melanoma. another and trial shows 75% pathological response pembro + lenvatinib. 55% mpr. poster 793. 
Co-Medical Director and Medical Oncologist Melanoma Institute Australia.